Grifols growing portfolio of specialized clinical diagnostics is designed to detect and monitor treatment of infectious, autoimmune, and neurodegenerative diseases. Our comprehensive autoimmune portfolio of hardware, software, and reagents allow laboratories to simplify routine autoimmune testing, streamline workflow, and reduce hands-on time in the laboratory.
HELIOS – All-in-One IFA Processing and Reading
The HELIOS System is the only FDA cleared instrument to provide all-in-one IFA HEp-2 slide processing and reading on one platform. The HELIOS combines reliable hardware, intuitive software, and quality reagents to transform the autoimmune testing workspace.
The HELIOS is FDA cleared for the following assays:
- HEp-2 (7 patterns)
- ANCA Ethanol and Formalin (2 patterns)
- Crithidia luciliae – nDNA (1 pattern)
SQII – True Open Automation
SQII is a compact, flexible, open system ideal for running any ELISA test from autoimmune and infectious disease, to therapeutic drug monitoring. SQII was designed for high efficiency and reliability. The system has only a few moving parts which makes it simple to maintain and easy to use. SQII is adapted to run AESKULISA assays and can simultaneously process two 96-well microplates and up to four different assays using the AESKULISA racks and reagents, or twelve assays using standard racks.
The AESKULISA menu encompasses 155 autoimmune tests including 30 FDA cleared tests:
- 13 FDA approved tests for Rheumatology
- 6 FDA approved tests for Thrombosis
- 9 FDA approved tests for Gastroenterology
- 2 FDA approved tests for Vasculitis
| || |
HELIOS – All-in-One IFA Processing
SQII – True Open Automation
Grifols blood typing products cover the main demands of immunohematology laboratories, offering optimized technology for various testing needs and the expert support of a specialized global partner so that patients receive safer transfusions, right on time.
Discover how the DG Gel system is continuously growing by offering increased adaptability and making daily work easier. With scalable systems that adapt to laboratories' different throughput and capacities while using the same reagents and equivalent software, users can select the solution that is best suited for their typing needs.
- Designed to adapt to different workflow needs
- Developed to provide intuitive operation in a compact footprint
The new Erytra Eflexis1: Adaptability that fits your lab
Introducing the new Erytra Eflexis – the natural evolution in Grifols scalable, blood typing solutions. This truly flexible system allows laboratories to select the solution that is best suited to different workflow needs and capacities.
The Erytra and Erytra Eflexis are true scalable systems that offer different throughput and capacities, while using the same reagents and sharing the equivalent software suite. Therefore you can select the solution that is best suited for your laboratory.
| || || || |
Erytra Eflexis system
ID CORE XT2
The new ID CORE XT kit, part of the BLOODchip platform, provides extended blood group genotyping to support improved patient care.
ID CORE XT kit
- Do more to prevent alloimmunization, even in your frequently transfused patients
- Enhanced transfusion compatibility in patients with complex antibody profiles
- Reduce the workload involved in complex antibody workups
- Develop a more information-rich rare donor database to provide better-matched blood to the patients who need it most
Grifols Immunohematology Center & Clinical Laboratory
Grifols Immunohematology Center
Make your laboratory more productive to deliver the best possible patient care. Our CLIA reference laboratory at the Grifols Immunohematology Center provides testing and support for the most challenging cases, saving you time and resources that would otherwise be consumed by complex workups.
The Grifols Immunohematology Center gives you the tools to:
- Take the best possible precautions to avoid alloimmunization and transfusion reactions based on current scientific knowledge
- Take the best possible precautions to avoid HDFN (hemolytic disease of the fetus and newborn, based on current scientific knowledge) and unnecessary Rh immune globulin administration
- Strengthen your own expertise
Grifols Clinical Laboratory
Our lab offers specialized testing panels for selected medical needs like therapeutic drug monitoring and diagnosis of different genetic diseases like familial hypercholesterolemia (FH).
TDMonitor is a new panel of assays to measure levels of Infliximab (Remicade, Inflectra, Remsima), Adalimumab (Humira) or Vedolizumab (Entyvio) and the anti-drug antibodies. Test results support clinicians, hospitals, and laboratories, globally, in making therapeutic decisions, improving patient therapy strategy and reducing the risk of debilitating disease progression. TDMonitor assays were developed and validated by Grifols CLIA-certified Clinical Laboratory in San Marcos, Texas. Samples may be mailed to the Texas laboratory. Following testing of the sample, a complete report, that includes recommendations with references, is generated and then submitted to the health care provider in 5-7 days.
Grifols offers genetic tests to diagnose familial hypercholesterolemia (FH) by using the advanced sequencing technologies. FH is a condition present in 1 in 250 people worldwide. This genetic condition causes lifelong levels of high cholesterol, which can lead to early coronary artery disease.